Genzum gets backing from SG

SG's alternative investments division has increased its investment in pharmaceutical company GENZUM by up to $20 million with a portion of the investment reserved for additional growth capital. Dovi Frances, president of SG will join GENZUM's board.

DealsNorth AmericaUSBriefs